Benefits and Harms of Femtosecond Laser Assisted Cataract Surgery: A Systematic Review

December 2013

Prepared for:
Department of Veterans Affairs
Veterans Health Administration
Health Services Research & Development Service
Washington, DC 20420

Prepared by:
Evidence-based Synthesis Program (ESP) Center
Portland VA Medical Center
Portland, OR
Devan Kansagara, M.D., M.C.R., Director

Investigators:
Principal Investigator:
Ana Quiñones, Ph.D.

Co-Investigators:
Ken Gleitsmann, M.D., M.P.H.
Michele Freeman, M.P.H.
Rochelle Fu, Ph.D.
Maya O’Neil, Ph.D.
Makalapua Motu’apuaka, B.S.
Devan Kansagara, M.D., M.C.R.
PREFACE

Quality Enhancement Research Initiative’s (QUERI) Evidence-based Synthesis Program (ESP) was established to provide timely and accurate syntheses of targeted healthcare topics of particular importance to Veterans Affairs (VA) managers and policymakers, as they work to improve the health and healthcare of Veterans. The ESP disseminates these reports throughout VA.

QUERI provides funding for four ESP Centers and each Center has an active VA affiliation. The ESP Centers generate evidence syntheses on important clinical practice topics, and these reports help:

- develop clinical policies informed by evidence,
- guide the implementation of effective services to improve patient outcomes and to support VA clinical practice guidelines and performance measures, and
- set the direction for future research to address gaps in clinical knowledge.

In 2009, the ESP Coordinating Center was created to expand the capacity of QUERI Central Office and the four ESP sites by developing and maintaining program processes. In addition, the Center established a Steering Committee comprised of QUERI field-based investigators, VA Patient Care Services, Office of Quality and Performance, and Veterans Integrated Service Networks (VISN) Clinical Management Officers. The Steering Committee provides program oversight, guides strategic planning, coordinates dissemination activities and develops collaborations with VA leadership to identify new ESP topics of importance to Veterans and the VA healthcare system.

Comments on this evidence report are welcome and can be sent to Nicole Floyd, ESP Coordinating Center Program Manager, at nicole.floyd@va.gov.

TABLE OF CONTENTS

EXECUTIVE SUMMARY
Background.................................................................................................................................................... 1
Methods ......................................................................................................................................................... 1
Results ........................................................................................................................................................... 2
Discussion...................................................................................................................................................... 3
Conclusion ..................................................................................................................................................... 4
Summary of evidence table on the effects of femtosecond laser assisted cataract surgery................. 5

BACKGROUND .............................................................................................................................................. 6

METHODS
Topic Development........................................................................................................................................ 7
Search Strategy ............................................................................................................................................ 11
Study Selection ............................................................................................................................................ 11
Data Abstraction .......................................................................................................................................... 11
Study Quality ............................................................................................................................................... 12
Rating the Body of Evidence....................................................................................................................... 12
Data Synthesis ............................................................................................................................................. 12

RESULTS
Literature Flow ............................................................................................................................................ 13
Key Question 1: What is the evidence that FLACS is associated with better patient outcomes than
conventional cataract surgery? .............................................................................................................. 15
Key Question 2a: What are the adverse effects that have been reported for FLACS? ........................ 18
Key Question 2b: What is the evidence that FLACS is associated with a lower risk of adverse
effects than conventional cataract surgery? ...................................................................................... 19
Key Question 3: What is the evidence that the experience of the surgeon is associated with
adverse effects of FLACS? .................................................................................................................. 20
Ongoing Studies .......................................................................................................................................... 21

DISCUSSION .................................................................................................................................................. 29
Future Studies .............................................................................................................................................. 31
Conclusions .................................................................................................................................................. 32

REFERENCES ................................................................................................................................................. 33

TABLES
Table 1: Characteristics and findings of studies of femtosecond laser assisted cataract surgery........ 22
Table 2: Characteristics of upcoming studies presented at recent conference proceedings or
registered on ClinicalTrials.gov .............................................................................................................. 26
Table 3: Summary of the evidence on the effects of femtosecond laser assisted cataract surgery.... 32
FIGURES

Figure 1: Analytic Framework ................................................................. 10
Figure 2: Femtosecond laser assisted cataract surgery - literature flow diagram .................. 14
Figure 3: Corrected distance visual acuity (CDVA) in studies comparing femtosecond laser with conventional cataract surgery ................................................................. 17
Figure 4: Effective phacoemulsification time (EPT) in studies comparing femtosecond laser with conventional cataract surgery ........................................................................ 17

APPENDIX A: Search Strategy ..................................................................... 37

APPENDIX B: Inclusion/Exclusion Criteria ...................................................... 39

APPENDIX C: Eligibility Characteristics of Studies (PICOTS Table) ................... 40

APPENDIX D: Assessment of Methodologic Quality in Studies of Femtosecond Laser Assisted Cataract Surgery ............................................................... 41

APPENDIX E: Peer Review Comments and Responses ...................................... 45
EVIDENCE REPORT

BACKGROUND

The preferred method of removing cataracts in the developed world is phacoemulsification. Using this technique, ultrasonic energy softens the dense lens material of the cataract, which is then extracted from the eye with suction and irrigation. Current practice includes creating manual corneal incisions and anterior capsulotomies, followed by phacoemulsification. Recently these three manual procedures have been performed in an automated fashion with the use of the femtosecond laser (FSL). Several FSL systems have been approved by the FDA for use in the U.S. for some or all of these procedural steps in cataract surgery. FSL technology has been widely used in various refractive surgery applications in recent years. Studies have suggested decreased phacoemulsification energy use with FSL cataract surgery and have examined the potential advantages of more precise corneal incisions and capsulotomy formation.

Cataract surgery is a frequently performed operation in the VHA, with more than 49,000 performed in 2012. As a result, the VHA National Surgery Office has been tasked with making a recommendation regarding whether femtosecond lasers provide appropriate cost-benefit and risk-benefit ratios to support implementation for cataract surgery in the VA. Thus, an unbiased evidence review examining the potential benefits and adverse effects related to femtosecond laser assisted cataract surgery (FLACS) will aid VA leadership in determining policy for use of this technology. The purpose of this report is to systematically present the evidence regarding the effectiveness and safety of FLACS relative to conventional cataract surgery. Key questions were developed in conjunction with the stakeholders which address the effectiveness, safety, adverse consequences and economic implications of adopting FLACS into the VA system.
METHODS

TOPIC DEVELOPMENT

The following key questions guiding this systematic review were developed after a topic refinement process that included a preliminary review of published peer-reviewed literature, consultation with internal partners and investigators and consultation with content experts and key stakeholders.

Key Question 1: What is the evidence that FLACS is associated with better patient outcomes than conventional cataract surgery?

Population: Adults undergoing cataract surgery.

Considerations: Femtosecond laser surgery is relatively contraindicated in patients with: advanced glaucoma, high anxiety, tremors, dementia, facial or ocular anatomy that precludes adequate LASER docking (i.e. small palpebral fissures, prominent brows, irregular corneal surfaces) and previous refractive surgery or corneal opacities.

Intervention: Femtosecond laser technology is used in cataract surgery to assist or replace aspects of conventional cataract surgery, including corneal incisions, capsulotomy and lens fragmentation. Lasers at or near the point of commercial release include: Alcon LenSx (Alcon Laboratories, Fort Worth, TX, USA); OptiMedica Catalys (OptiMedica Corp, Santa Clara, CA, USA); LensAR (LensAR Inc, Winter Park, FL, USA); VICTUS (Bausch + Lomb, Aliso Viejo, CA, USA; and Technolas Perfect Vision GmbH, Munich, Germany); IntraLase FS; and iFS Laser Systems (Abbott Medical Optics, Abbott Park, IL, USA).

Only a subset of these lasers is currently FDA approved for cataract surgery. Still, this review is inclusive of studies concerning any femtosecond laser used for cataract surgery applications regardless of FDA status.

Comparators: Conventional cataract surgery, defined as small-incision, phacoemulsification with posterior-chamber intraocular lenses (IOL) implantation.

Outcomes: Short-term patient outcomes: visual acuity—post-operative day 1. Long-term patient outcomes: visual acuity—after post-operative day 1 (e.g., one week, one month, ninety days); quality of life measures.

Study design: Controlled studies including randomized controlled trials and non-randomized controlled clinical trials, as well as observational studies comparing FLACS to conventional cataract surgery.

Excluded study designs: Case reports, case series and studies that do not report primary data such as editorials and non-systematic reviews.

Timing: Our operational definition to be used for timing of patient outcomes is as follows:

- Short-term—patient outcomes on post-operative day 1
- Long term—patient outcomes > after post-operative day 1 (no upper limit).
Considerations: Standards for reporting timing of post-operative outcomes often have variable time-horizons. For example, potential harms such as CME or IOL decentration, may be reported from as early as post-operative day one or after months to years in some studies.

Setting: Any.

Key Question 2a: What are the adverse effects that have been reported for FLACS?

Key Question 2b: What is the risk of adverse effects from FLACS compared to the risk associated with conventional cataract surgery?

Population: Adults undergoing cataract surgery.

Intervention: Femtosecond laser technology is used to assist or replace steps in conventional cataract surgery, including corneal incisions, capsulotomy and lens fragmentation.

Comparators: Conventional cataract surgery.

Outcomes: Surgical complications (intra-operative and post-operative).

   Intra-operative: 1) capsular blockage syndrome
                    2) dislocated nucleus
                    3) capsular tear
                    4) docking failure

   Post-operative: 1) infection
                    2) retinal swelling/cystoid macular edema (CME)
                    3) corneal edema
                    4) intraocular (IOL) decentration

Study design: Controlled studies and observational study designs (cohort and case-control studies), case reports and case series.

Timing: Short-term—intraoperative, post-operative day 1. Long term—patient outcomes > after post-operative day 1 (no upper limit).

Setting: Any.

Key Question 3: What is the evidence that the experience of the surgeon is associated with adverse effects of FLACS?

Population: Adults undergoing cataract surgery.

Intervention: Femtosecond laser technology is used in cataract surgery to assist or replace aspects of conventional cataract surgery, including corneal incisions, capsulotomy and lens fragmentation.

Comparators: Conventional cataract surgery.

Study designs: Controlled studies and observational study designs including economic evaluation studies (cohort and case-control studies).
Excluded study designs: Case reports, case series and studies that do not report primary data such as editorials and non-systematic reviews.

Outcomes: Surgical complications (intra-operative and post-operative).

Intra-operative: 1) capsular blockage syndrome
2) dislocated nucleus
3) capsular tear
4) docking failure

Post-operative: 1) infection
2) retinal swelling/cystoid macular edema (CME)
3) corneal edema
4) intraocular (IOL) decentration

Timing: Short-term—patient outcomes on post-operative day 1. Long term—patient outcomes > after post-operative day 1 (no upper limit).

Setting: Any.

Appendix C presents these eligibility criteria for considered studies in a PICOTS (Population, Intervention, Comparators, Outcomes, Timing and Setting) table. Figure 1 illustrates the analytic framework that guided our review and synthesis.
Figure 1: Analytic Framework

Adults undergoing cataract surgery → FLACS vs. conventional cataract surgery

KQ1

Short-term Outcome:
• Visual acuity post-operative at day 1

Long-term Outcomes:
• Visual acuity after post-operative day 1 (e.g., 1 week, 1 month or 90 days)
• Quality of life

KQ2a, KQ2b

Adverse events:
• Intra-operative complication
  ○ Capsular blockage syndrome
  ○ Dislocated nucleus
  ○ Capsular tear
  ○ Docking failure
• Post-operative
  ○ Infection
  ○ Retinal swelling/Cystoid Macular Edema (CME)
  ○ Intraocular (IOL) decentration
  ○ Corneal edema

KQ3

Context: Experience of surgeon
SEARCH STRATEGY

Search strategies were developed in consultation with a research librarian from database inception to May 2013. We conducted a primary review of the literature by systematically searching, reviewing and analyzing the scientific evidence as it pertained to the research questions. To identify relevant articles, we began by searching MEDLINE®, the Cochrane library, ClinicalTrials.gov, premarket notification 510(k) summaries from the FDA and conference proceedings of societies for ophthalmology and refractive surgery. Searches were conducted from April 2013 to July 2013, with no limit on year of publication.

We searched ClinicalTrials.gov to identify in-progress or unpublished studies. We searched conference proceedings of ophthalmologic societies and topic specific journals, including the following: The American Society of Cataract and Refractive Surgery; Journal of Cataract & Refractive Surgery; American Academy of Ophthalmology; Ophthalmology; International Society of Refractive Surgery; American Academy of Ophthalmic Executives; The Foundation of the American Academy of Ophthalmology; The Royal College of Ophthalmologists; COS Conference Papers Index; and Proceedings First (OCLC). Appendix A provides the search strategy in detail. We obtained additional articles from reference lists of pertinent studies, reviews, editorials and by consulting experts. All citations were imported into an electronic database (EndNote X1).

STUDY SELECTION

Two reviewers assessed abstracts of citations identified from literature searches for relevance. Full-text articles of relevant abstracts were retrieved for further review. Each article retrieved was independently reviewed by two reviewers using eligibility criteria (Appendix B). Included studies were published in the English language and involved adults undergoing cataract surgery using femtosecond laser technologies.

Using pre-specified inclusion/exclusion criteria, titles and abstracts were reviewed for potential relevance to the key questions. At the full-text screening stage, two independent reviewers assessed each study. Disagreements were discussed to come to a final decision on inclusion/exclusion. If the two independent reviewers could not come to an agreement, a third reviewer assessed the study in question. For all excluded studies, full-text reviewers also came to unanimous agreement on the reason for exclusion. Articles meeting eligibility criteria were included for data abstraction.

DATA ABSTRACTION

Data from published reports were abstracted into a customized database by one investigator and reviewed for accuracy by a second investigator. From each study, we abstracted the following: study design, objectives, setting (country, institution information), population characteristics (including sex, age, medical comorbidities), subject eligibility and exclusion criteria, number of subjects, duration of follow-up, the study and comparator interventions, health outcomes, adverse events and number and experience of the surgeons.
STUDY QUALITY

We adapted the Newcastle Ottowa tool⁹ to assess the quality of observational studies. For randomized studies, we used the Cochrane Collaboration tool for assessing the risk of bias. Two reviewers independently assessed the quality of each study and disagreements were resolved through discussion. We added additional criteria as necessary to account for methodological issues specific to this subject area, such as financial conflicts of interest and the number of studies produced by a small number of authors and coauthors (i.e., same team replication). We did not report an overall summary assessment for observational studies because there are no validated criteria for doing so.¹⁰

RATING THE BODY OF EVIDENCE

We assessed the overall quality of evidence for outcomes using a method developed by the GRADE Working Group.¹¹ We present the summary of evidence in Table 3. The GRADE method considers the consistency, coherence and applicability of a body of evidence, as well as the internal validity of individual studies, to classify the grade of evidence across outcomes as follows:

- High = Further research is very unlikely to change our confidence on the estimate of effect.
- Moderate = Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
- Low = Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
- Very Low = Any estimate of effect is very uncertain.

DATA SYNTHESIS

We summarized the primary literature by abstracting relevant data, developing data tables and qualitatively synthesizing the literature for each key question. We determined the feasibility of completing a quantitative synthesis (i.e., meta-analysis) to estimate summary effects depending on the volume of relevant literature, conceptual homogeneity of the studies and completeness of results reporting. We conducted meta-analyses of commonly reported outcomes, following the MOOSE guidelines for conducting meta-analyses of observational studies.¹² All analyses were conducted using StataIC 11 (StataCorp, College Station, Texas). We assessed the presence of statistical heterogeneity among the studies by using standard chi-square tests and the magnitude of heterogeneity by using the $I^2$ statistic.¹³ We explored models using both mean and ratio of means based on a random effects model. However, because of concerns of heterogeneity among studies we do not report the combined estimates and instead present forest plots as a visual aid to illustrate individual study results.
RESULTS

LITERATURE FLOW

We reviewed 468 titles and abstracts from the electronic search and identified 436 additional references through manual searching of reference lists, input from technical advisors and reviewing conference proceedings of ophthalmologic societies for recent unpublished or ongoing studies.

After applying inclusion/exclusion criteria at the abstract level, seventy full-text articles were reviewed, as shown in Figure 2. Of the full-text articles, we rejected fifty-four that did not meet our inclusion criteria.
Figure 2: Femtosecond laser assisted cataract surgery – literature flow diagram

468 published articles identified from electronic searches of databases and specific journals:
- 76 from MEDLINE® on 05/08/2013
- 3 from the Cochrane library (Central Register of Controlled Trials and Database of Systematic Reviews) on 03/18/2013
- 14 from Clinicaltrials.gov on 04/07/2013
- 6 premarket notification 510(k) summaries from the FDA on 05/09/2013
- 369 from journals specific to ophthalmology or cataract surgery on 05/08/2013

436 citations identified from conference proceedings of societies, reference lists of review articles, and manual searches for recent, unpublished or ongoing studies.

904 citations compiled for review of titles and abstracts.

834 titles and abstracts excluded for lack of relevance.

70 potentially relevant articles or ongoing research abstracts retrieved for further review.

19 abstracts of unpublished, recent or ongoing studies.

15 published studies addressing one or more key questions:
- 9 studies reporting the benefits of FLACS compared with conventional cataract surgery (KQ1).
- 9 studies reporting the unique risks of FLACS (KQ2a) or risks compared to conventional cataract surgery (KQ2b).
- 2 studies addressing intra-/post-operative risks with regard to the experience of the surgeon (KQ3).

34 excluded articles:
- Not relevant to key questions = 7
- Intervention not in scope = 1
- Studied outcomes not in scope = 2
- Excluded study design or study contains no primary data = 6
- Retained for background, discussion, methods or other contextual purposes = 18
KEY QUESTION 1: What is the evidence that FLACS is associated with better patient outcomes than conventional cataract surgery?

Summary of findings
We identified nine studies addressing the comparative effectiveness of FLACS versus conventional surgery, including three small to medium-sized randomized controlled trials. Six of these studies (and all three of the randomized controlled trials) were conducted at Semmelweis University, Budapest, Hungary, all surgeries having been performed by the same surgeon, using the Alcon LenSx laser. Two studies were conducted in an ophthalmology group practice, at Launceston Eye Hospital, Tasmania, Australia, using the OptiMedica Catalys laser. Sample sizes in these studies ranged from 25 to 400 patients, with follow-up periods extending from two weeks to one year.

The most commonly reported relevant outcomes in these comparative studies were: post-operative corrected distance visual acuity (CDVA); and, effective phacoemulsification time (EPT). We conducted a meta-analysis of CDVA and EPT, but heterogeneity precluded calculation of a reliable summary effect estimate. The results of individual studies are presented in Figures 3 and 4. Overall, there was low evidence of comparative benefit of FLACS from three randomized controlled trials and six observational studies. There were no significant differences noted between groups for CDVA outcomes. EPT outcomes were mixed, with results either comparable between FSL and conventional cataract surgery groups or favoring FSL groups. No studies addressed quality of life measures. Methodological concerns were noted regarding the generalizability of studies conducted from limited sites and potential sample selection bias from enrollment into FSL and conventional surgery groups.

Detailed findings
Table 1 shows the detailed characteristics and findings of the included comparative studies.

A randomized trial (N=134) with 77 patients in the FSL group and 57 patients in the conventional cataract surgery group utilized the Alcon LenSx laser. Baseline age between groups was similar, with cataract density not reported. Reported post-operative CDVA at twelve weeks was 0.93±0.87 in the FSL group and 0.95±0.91 in the conventional group (p>0.05).

Another randomized trial (N=45) compared a FSL group (n=25) versus a conventional group (n=20) using the Alcon LenSx laser. At one year, post-operative CDVA was measured as .97±.06 for the FSL group versus .92±.09 for the conventional group (p=.03).

One study (n=400) enrolled consecutive patients electing for FSL (n=200). Patients who did not elect FSL underwent conventional phacoemulsification cataract surgery (n=200) and were considered the control group. Five surgeons participated in this study, for which the OptiMedica Catalys laser was used in the FSL arm. Both groups were statistically similar at baseline in age and cataract density. EPT was reported as significantly decreased in the FSL group (4.3 vs 14.3 seconds; p<0.001).

Another study by the same author (N=201) was a case-control design, with a single surgeon using the OptiMedica Catalys laser in the FSL cases (n=150), compared to conventional cataract surgery controls (n=51). Baseline demographics and cataract density were similar statistically between
groups. CDVA outcomes at three weeks post-operatively measured 0.67 in both groups (p>0.05). EPT was significantly decreased in the FSL group (2.33±2.28 vs 14.24±10.90 seconds; p<0.0001).

Another study (N=91) compared FSL groups (n=48) with conventional surgery groups (n=43), using the Alcon LenSx laser. Baseline age and gender distribution was similar between groups but cataract density was not reported. At six months, post-operative CDVA was reported as as .97±.08 in the FSL group and .97±.06 in the conventional group (p>.05).

One study (N=76) enrolled equal groups (n=38) of FSL and conventional surgery patients, using the AlconLenSx laser. Demographic characteristics and cataract density at baseline were reported as being similar between the groups. The study excluded patients with denser cataracts, low cooperation and FSL procedure contraindications such as corneal scarring. EPT was reported as 0.10±0.12 for the FSL group and 0.12±0.13 seconds for the conventional group (p>0.05).

Another study (N=40) enrolled patients into FSL (n=20) and conventional groups (n=20) using the Alcon LenSx laser. Outcomes reported which compared FSL and conventional surgery groups were EPT (0.08 for FSL vs 0.08 for conventional; p=0.94) and one month post-operative CDVA (0.83±0.65 for FSL vs 0.95±0.87 for conventional; p-value not reported).

A final study (N=25) enrolled patients in FSL (n=12) and conventional surgery (n=13) groups with similar baseline demographic characteristics, with cataract density not reported. EPT was reported as not statistically different between groups. Eight week post-operative CDVA was measured as 1.0±0.0 for the FSL group and .95±.08 for the conventional group (p-value not reported).

**Meta-analyses of CDVA and EPT**

Figures 3 and 4 present plots of meta-analyses conducted on CDVA and EPT outcomes. Relatively few studies reported these outcomes in a consistent and combinable manner. We identified four studies for the meta-analysis of CDVA and four studies for the meta-analysis of EPT. Given the moderate to substantial heterogeneity among studies (for CDVA I-squared=63.9%, p = 0.040; for EPT I-squared=94.1%, p = 0.000), a summary estimate of the effect is unreliable. Instead, we present the forest plots as visual aids to illustrate individual study results.

The scales for CDVA used across studies were consistent when converted to decimal units, therefore we used mean difference to combine study results. We found moderate heterogeneity among studies. Consequently, we conducted a sensitivity analysis by excluding a presumed outlying study. We found that this exclusion did not alleviate concerns with heterogeneity, nor did it change the substantive findings of the meta-analytic results. As a result, we included all four studies in the meta-analyses, represented in Figure 3 which illustrates no significant difference in CDVA for patients undergoing FSL or conventional procedures.

For EPT, we used the ratio of the mean to reduce the variation among studies and estimated the relative difference in EPT. Despite these efforts, there was still significant heterogeneity among studies. We would have included one additional study in the meta-analysis, but this study did not report a point estimate for EPT and could not be included. Figure 4 shows what appears to be a reduction of mean EPT in the FLACS group, compared to the conventional group. However, since the 95% confidence interval includes one, this difference is not significant.
Figure 3: Corrected distance visual acuity (CDVA) in studies comparing femtosecond laser with conventional cataract surgery

<table>
<thead>
<tr>
<th>Study</th>
<th>N, mean (SD) Treatment</th>
<th>N, mean (SD) Control</th>
<th>Weight</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mihaltz, 2011</td>
<td>0.05 (0.01, 0.09)</td>
<td>43, .97 (.08)</td>
<td>51, .97 (.06)</td>
</tr>
<tr>
<td>Nagy, 2012</td>
<td>0.00 (-0.03, 0.03)</td>
<td>12, 1 (.004)</td>
<td>13, .95 (.08)</td>
</tr>
<tr>
<td>Ecsedy, 2011</td>
<td>-0.12 (-0.25, 0.00)</td>
<td>20, .832 (.27)</td>
<td>20, .955 (.0978)</td>
</tr>
<tr>
<td>Abell, 2013</td>
<td>0.00 (-0.03, 0.03)</td>
<td>150, .67 (.118)</td>
<td>51, .67 (.0793)</td>
</tr>
<tr>
<td>Overall (I-squared = 63.9%, p = 0.040)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Figure 4: Effective phacoemulsification time (EPT) in studies comparing femtosecond laser with conventional cataract surgery

<table>
<thead>
<tr>
<th>Study</th>
<th>Ratio of Means (95% CI)</th>
<th>Weight</th>
</tr>
</thead>
<tbody>
<tr>
<td>Takacs, 2012</td>
<td>0.83 (0.50, 1.39)</td>
<td>24.02</td>
</tr>
<tr>
<td>Ecsedy, 2011</td>
<td>1.00 (0.54, 1.84)</td>
<td>22.90</td>
</tr>
<tr>
<td>Abell, 2012</td>
<td>0.30 (0.24, 0.37)</td>
<td>26.69</td>
</tr>
<tr>
<td>Abell, 2013</td>
<td>0.16 (0.13, 0.21)</td>
<td>26.38</td>
</tr>
<tr>
<td>PL Overall (I-squared = 94.1%, p = 0.000)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
KEY QUESTION 2A: What are the adverse effects that have been reported for FLACS?

Summary of findings

Seven studies were identified addressing adverse effects unique to FLACS. Sample sizes in these studies ranged from 25 to 1300 patients, with follow-up periods extending from immediately following the procedure to three months post-operative.

We grouped the adverse event outcomes in these studies by either: 1) those occurring as a result of difficulties with the laser-patient interface; or, 2) the change in intraocular pressure (IOP) measured during the FLACS procedure. Five studies reported difficulties related to the laser interface with the ocular surface (including the orbital structures). Two studies measured intraocular pressure (IOP) fluctuation during FLACS procedures. A small proportion of patients experienced suction breaks, second docking attempts and aborted procedure adverse events. FSL application is also associated with an increase in IOP. Overall, we found moderate to low strength of evidence for adverse events with methodological concerns from enrollment criteria used for FSL surgery groups.

Detailed findings

Laser interface events

One study compared EPT in two groups of patients (n=80 per group) undergoing FLACS with two different laser grid-sizes. In both groups, using the OptiMedica Catalys FSL, a total of twelve patients required a second docking attempt. No other intra-operative or subsequent adverse events were noted in either group after four weeks of follow-up.

A case series study (N=100) of IOP measurements during FLACS noted no patients had suction loss during FSL (Catalys) treatment. No adverse events were reported at the one hour post-operative timepoint.

A comparative safety and effectiveness study of 400 patients (n=200 per group), reported four patients in the FSL (Catalys) group, for whom the laser procedure was aborted. One patient was claustrophobic, one with kyphosis made positioning unsafe and two patients had excessive movement during the procedure.

A case series of the initial 200 patients undergoing FLACS (Alcon LenSx) in a single group practice reported intraoperative complications of this cohort. Mean docking attempts were reported as 1.5 per eye. Five eyes had suction breaks during the FSL procedure, with no adverse events noted with the manual completion of the surgeries. A continuation study of this same group’s experience, using the same FSL platform, reported intraoperative complications of FLACS for a subsequent series of 1300 patients. No additional adverse effects unique to FLACS were noted, though data related to surgical experience was reported (see findings for Key Question 3).

Intraocular pressure events

The interface of any of the FSL platforms with the optical surface causes an increase in intraocular pressure (IOP). This occurs due to applanation and/or suction applied during FSL
docking and laser application. This laser-patient interface must be stable throughout the phases of imaging, capsulotomy, corneal incisions and photodisruptive pre-fragmentation of the cataract. The various FSL platforms use different docking mechanisms, which can affect the degree to which the IOP increases during the FLACS procedure.\(^1\) Both of the IOP studies included in this review utilized the OptiMedica Catalys FSL.

One case series (N=100) recorded IOP at two time-points—during and one hour following the FLACS procedure.\(^22\) Mean IOP increased to 27.6 ±5.5 mmHg in this cohort. Patients were queried post-operatively and none reported experiencing amaurosis (blindness), during FLACS.

An additional case series study to analyze IOP during FLACS (N=25), reported measurements at baseline and at various time-points.\(^25\) Mean baseline IOP (17.4±2.4 mmHg), increased to 36.0±4.4 mmHg during FSL application. This represented a mean increase from baseline of 18.5±4.7 mmHg.

**KEY QUESTION 2B: What is the risk of adverse effects from FLACS compared to the risk associated with conventional cataract surgery?**

**Summary of findings**

Nine studies addressed the adverse effects of FLACS compared to conventional cataract surgery. Sample sizes in these studies ranged from 25 to 400 patients, with follow-up periods extending from one week to one year.

We grouped the adverse event outcomes of these studies by the ocular structures which were affected. Five of these studies reported, variously: capsulotomy configuration, position and the resultant effects on IOL decentration and refractive outcomes. Two of these studies reported post-operative corneal edema by measuring either corneal thickness or corneal endothelial cell loss. An additional two studies compared post-operative macular thickness and morphology, as measured by optical coherence tomography (OCT). The FSL and control groups were similar for post-operative corneal thickness and macular edema measurements, with corneal endothelial cell loss decreased in the FSL group in one study. Overall, we found moderate to low strength of evidence for comparative adverse events with methodological concerns from enrollment criteria used for the FSL and conventional surgery groups.

**Detailed findings**

**Capsulotomy sequelae**

Five comparative studies of capsulotomy characteristics reported multiple aberrometry and geometric measurement outcomes.\(^6,14,15,17,26\) However, none of the prioritized adverse events were reported in any of these studies (see Appendix C).

**Corneal morphology and function**

One study (n=76) compared central corneal thickness by pachymetry measurement at one month post-operatively in equal numbers of patients. At enrollment, patients with dense cataracts were excluded from participation in the study.\(^18\) These authors reported no statistical difference
between corneal thickness between FSL vs. conventional groups (545±31µm vs. 557±42 µm; p>.05) Another study reported decreased corneal endothelial cell loss in the FSL group (n=150) vs. the control group (n=51) at three weeks post-operatively (-143.8±208.3 vs -224±188.95; p=0.02).16

**Macular morphology**

Two studies compared macular thickness between FSL and conventional surgery groups via OCT measurements. One of these studies (n=25) noted no statistically significant differences in macular thickness between groups in all but one retinal layer post-operatively at eight weeks.20 Here, the outer nuclear layer was thicker in the control group (96.5±10.46µm vs 87.54±10.31µm; p=.04). Another study (n=40) measured macular thickness post-operatively at one month, reporting no significant differences between groups in macular total volume, foveal or outer macular ring thickness.19

**KEY QUESTION 3: What is the evidence that the experience of the surgeon is associated with adverse effects of FLACS?**

**Summary of findings**

Three studies reported outcomes relevant to the experience of the surgeon in performing the FLACS procedure. Sample sizes in these studies ranged from 200 to 1300 patients, with follow-up periods extending from two weeks to three months. Overall, one of the studies found no significant differences between outcomes for initial and subsequent groups of patients undergoing FLACS, while on the other hand two studies from the same team of researchers found significantly fewer complications associated with greater experience with FLACS.

There were methodological concerns from enrollment criteria used for the FSL and conventional surgery groups.

**Detailed findings**

One study compared the safety and effectiveness of FSL to conventional surgery in 200 consecutive patients who elected FSL or conventional surgery procedures.4 Further sub-analysis of the FSL group into initial (n=100) and subsequent (n=100) patients reported outcomes for EPT and docking attempts. No statistically significant differences were noted between initial and subsequent groups for either of these FSL parameters (mean EPT: 3.52±4.18 for FSL vs. 4.75±5.22 for conventional group; p=0.0674; mean docking attempts: 1.49±0.64 for FSL vs. 1.36±0.79 for conventional group; p=0.2025).

Another study compared intraoperative complications in four groups of consecutive patients undergoing FLACS (n=50 in each group) who were followed for three months.21 The number of mean docking attempts was greater in the initial 100 patients than in the subsequent 100 patients (1.85 for FSL vs 1.2 for conventional group; p<0.05). The seven surgeons participating in this study were all from a single group practice. Three of these surgeons had prior “extensive” experience with the FSL in LASIK surgery. The study noted these “refractive surgeons” had statistically fewer complications than did the “non-refractive surgeons” in their first 100 cases.
No significant difference in complications between these surgeon groups was noted after these initial 100 cases.

An extension of the above study\textsuperscript{23} reported complication rates in a subsequent consecutive patient group (n=1300) treated with FLACS by the same surgical group practice, compared to the initial group of 200 patients.\textsuperscript{24} Patients were followed for three months. Complications were significantly decreased in the subsequent group for docking attempts (1.5 for FSL vs 1.05 for conventional group), anterior capsular tears (4% for FSL vs 0.31% for conventional group), posterior capsular tears (3.5% for FSL vs 0.31% for conventional group) and posterior lens dislocation (2% for FSL vs 0% for conventional group). The reported p-values for all comparisons were p<0.001.

**ONGOING STUDIES**

We reviewed recent conference proceedings from ophthalmologic societies for topic relevance. We coded conference abstracts that potentially address one or more of our key questions and describe the study characteristics in Table 2.
### Table 1: Characteristics and findings of studies of femtosecond laser assisted cataract surgery

<table>
<thead>
<tr>
<th>Author, Year; Study Setting</th>
<th>Study objectives</th>
<th>Study Design; Number of Patients; Length of Follow-up; Laser Used</th>
<th>Mean age; % male; cataract density (LOC III score)</th>
<th>KQ 1: Benefits</th>
<th>KQ 2: Adverse events</th>
<th>KQ 3: Surgeon experience</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conrad-Hengerer, 2012&lt;sup&gt;21&lt;/sup&gt;</td>
<td>Laser grid-size efficacy/safety study</td>
<td>Prospective cohort study of two FLACS techniques—no conventional surgery comparator (single surgeon)</td>
<td></td>
<td></td>
<td>EPT:</td>
<td>Intraoperative:</td>
</tr>
</tbody>
</table>
| University of Bochum, Germany | | | | | Tx group 1 (350 grid): 71±12; 32%; 3.7±08 | -Free-floating anterior capsule noted in all eyes
-12.2° docking attempts |
| | | N=160 patients
4 weeks
OptiMedica Catalys | | | | Post operative: None noted |
| Schultz, 2013<sup>22</sup>| Record IOP at various time-points during FLACS | Case series (2 surgeons) | 70±12; 51%; NR | | | |
| University of Bochum, Germany | | N=100 patients
1 hour
OptiMedica Catalys | | | | |
| Mihaltz, 2011<sup>17</sup>
Semmelweis University Budapest, Hungary | Compare FSL and conventional capsulotomies | Prospective cohort study of FLACS and conventional surgery (single surgeon) | | | CDVA: | Intraoperative: |
| | | | | | Tx group = 75.0; 21%; NR | 27.6±5.5mmHg increase in mean IOP |
| | | N=91 patients
6 months
Alcon LenSx | | | C group = 70.7; 18%; NR | | |
| Nagy, 2012<sup>25</sup>
Semmelweis University Budapest, Hungary | Compare FSL and conventional OCT macular thickness changes | Prospective cohort study of FLACS and conventional surgery (single surgeon) | | | CDVA: | |
| | | | | | Tx group = 55.17±17.25; 58.3%; NR | None noted |
| | | N=25 patients
8 weeks
Alcon LenSx | | | C group = 62.00±14.27; 38.5%; NR | | |

<sup>CONTENTS</sup> 22
<table>
<thead>
<tr>
<th>Author, Year; Study Setting</th>
<th>Study objectives</th>
<th>Study Design; Number of Patients; Length of Follow-up; Laser Used</th>
<th>Mean age; % male; cataract density (LOC III score)</th>
<th>KQ 1: Benefits</th>
<th>KQ 2: Adverse events</th>
<th>KQ 3: Surgeon experience</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nagy, 2011&lt;sup&gt;26&lt;/sup&gt; Semmelweis University Budapest, Hungary</td>
<td>Compare FSL and conventional capsulotomies and IOL decentration</td>
<td>Randomized trial of FLACS and conventional surgery (single surgeon)</td>
<td>Tx group: 65±13; 27.8%; NR</td>
<td>NA</td>
<td>NR</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td></td>
<td>N=111 patients 1 week Alcon LenSx</td>
<td>C group: 68±15; 29.8%; NR</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kranitz, 2012&lt;sup&gt;25&lt;/sup&gt; Semmelweis University Budapest, Hungary</td>
<td>Compare FSL and conventional IOL decentration and tilt</td>
<td>Randomized trial of FLACS and conventional surgery (single surgeon)</td>
<td>Tx group: 63.55±13.65; 25%; NR</td>
<td>CDVA: Tx group=0.97±0.06 C group= 0.92±0.09 p=0.03</td>
<td>NR</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td></td>
<td>N=45 patients 1 year Alcon LenSx</td>
<td>C group: 68.24±10.77; 8%; NR</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kranitz, 2011&lt;sup&gt;6&lt;/sup&gt; Semmelweis University Budapest, Hungary</td>
<td>Compare FSL and conventional capsulotomy sizing and position</td>
<td>Prospective cohort study of FLACS and conventional surgery (single surgeon)</td>
<td>Tx group: 63.78±13.97; 25%; NR</td>
<td>NA</td>
<td>NR</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td></td>
<td>N=40 patients 1 year Alcon LenSx</td>
<td>C group: 71.60±1.34; 30%; NR</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Takacs, 2012&lt;sup&gt;3&lt;/sup&gt; Semmelweis University Budapest, Hungary</td>
<td>Compare FSL and conventional corneal edema</td>
<td>Prospective cohort study of FLACS and conventional surgery (single surgeon)</td>
<td>Tx group: 65.18±12.42; 26.3%; 2.32±.97</td>
<td>EPT: Tx group=0.10±0.12s C group= 0.12±0.13s p&gt;.05</td>
<td>Postoperative: Central corneal thickness Tx group=545±31 µm C group= 557±42 µm p&gt;.05</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td></td>
<td>N=76 patients 1 month Alcon LenSx</td>
<td>C group: 66.9±10.99; 39.5%; Schiempflug nuclear density 2.13±1.22</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Filkorn, 2012&lt;sup&gt;4&lt;/sup&gt; Semmelweis University Budapest, Hungary</td>
<td>Compare FSL and conventional IOL power calculation and refractive outcome</td>
<td>Randomized trial of FLACS and conventional surgery (single surgeon)</td>
<td>Tx group: 65.18±12.6; NR; NR</td>
<td>CDVA: Tx group=0.93±0.87 C group= 0.95±0.91 p&gt;.05</td>
<td>NR</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td></td>
<td>N=134 patients 12 weeks Alcon LenSx</td>
<td>C group: 64.37±12.37; NR; NR</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Author, Year; Study Setting</td>
<td>Study objectives</td>
<td>Study Design; Number of Patients; Length of Follow-up; Laser Used</td>
<td>Mean age; % male; cataract density (LOC III score)</td>
<td>KQ 1: Benefits</td>
<td>KQ 2: Adverse events</td>
<td>KQ 3: Surgeon experience</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>-----------------</td>
<td>---------------------------------------------------------------</td>
<td>-----------------------------------------------</td>
<td>----------------</td>
<td>---------------------</td>
<td>--------------------------</td>
</tr>
<tr>
<td>Ecsedy, 2011&lt;sup&gt;19&lt;/sup&gt;</td>
<td>Compare FSL and conventional macular thickness</td>
<td>Prospective cohort of FLACS and conventional surgery (single surgeon)</td>
<td>Tx group: 64 (median); 40%; NR</td>
<td>CDVA (median): Tx group=0.83±0.65 C group= 0.95±0.87</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Semmelweis University Budapest, Hungary</td>
<td></td>
<td>N=40 patients 1 month Alcon LenSx</td>
<td>C group: 66 (median); 25%; NR</td>
<td>EPT (median, IQR): Tx group=0.08s (0.03-0.12) C group= 0.08s (0.03-0.15) p=0.94</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abell, 2012&lt;sup&gt;4&lt;/sup&gt;</td>
<td>Compare FSL and conventional phacoemulsification safety and effectiveness</td>
<td>Parallel cohort study of FLACS and conventional surgery (5 surgeons)</td>
<td>Tx group: 73.3±9.9; 48%; 2.81±.82 (Pentacam Nuclear Staging)</td>
<td>EPT: Tx group=4.3 sec C group= 14.3 sec p&lt;0.0001</td>
<td>Intraoperative: Reported for the Tx group, Imperfect capsulotomy= 0.5%; Focal adhesions= 2%; Reduction of pupil size= 3%; Capsular rupture= 0.5% Aborted (claustrophobia), n=1 Aborted (unsafe positioning), n=1 Aborted (patient movement), n=2</td>
<td>EPT: 1&lt;sup&gt;st&lt;/sup&gt; 100 cases=3.52+-4.18 secs 2&lt;sup&gt;nd&lt;/sup&gt; 100 cases=4.75+-5.22 secs; P=0.0674</td>
</tr>
<tr>
<td>Abell, 2013&lt;sup&gt;16&lt;/sup&gt;</td>
<td>Compare FSL and conventional phacoemulsification, visual outcomes and endothelial loss</td>
<td>Case control study of FLACS and conventional surgery (single surgeon)</td>
<td>Tx group: 72.5±10.5; 46%; 2.52±0.71 (Pentacam Nuclear Staging)</td>
<td>CDVA: Tx group=0.67 C group= 0.67 p&gt;0.05 EPT: Tx group=2.33±2.28s C group=14.24±10.90 s p&lt;0.0001</td>
<td>Postoperative: Endothelial loss Tx group= -143.8±208.3 C group= -224±188.95 p=0.022</td>
<td>NA</td>
</tr>
<tr>
<td>Kerr, 2013&lt;sup&gt;25&lt;/sup&gt;</td>
<td>Analyze the course of IOP during FSL cataract surgery</td>
<td>Prospective non-comparative cohort study</td>
<td>72.5±7.7; 40%; NR</td>
<td>NA</td>
<td>Intraoperative: Mean baseline IOP=17.5±2.4mmHg Vacuum On IOP=28.9±3.2mmHg FSL application=36.0±4.4 mmHg p&lt;0.001 (1-way ANOVA compared to baseline)</td>
<td>NA</td>
</tr>
</tbody>
</table>
### Benefits and Harms of Femtosecond Laser Assisted Cataract Surgery

<table>
<thead>
<tr>
<th>Study Setting</th>
<th>Study objectives</th>
<th>Study Design; Number of Patients; Length of Follow-up; Laser Used</th>
<th>Mean age; % male; cataract density (LOC III score)</th>
<th>KQ 1: Benefits</th>
<th>KQ 2: Adverse events</th>
<th>KQ 3: Surgeon experience</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vision Eye Institute, Chatswood, Australia</td>
<td>Describe intraoperative complications and evaluate learning curve with FLS cataract surgery</td>
<td>Prospective non-comparative cohort study (7 surgeons)</td>
<td>Initial Tx group: 69±9.8; NR; NR</td>
<td>NA</td>
<td>Intraoperative*: -mean docking attempts=1.5 -suction breaks=5 eyes -small anterior capsule tags=10.5% -posterior capsular rupture=3.5%</td>
<td>Complications with increasing surgeon experience (docking attempts; anterior capsular tears; post capsular tears; IOL dislocation)*: 1st 200 cases= 1.5; 4%; 3.5%; 2% 2nd 1300 cases= 1.05; 0.31%; 0.31%; 0% p&lt;0.001 for all comparisons</td>
</tr>
</tbody>
</table>

*These findings pertain to the initial study of N=200 patients

Abbreviations: C = Conventional cataract surgery group; Tx = femtosecond laser cataract surgery treatment group; N = number of subjects; LOC III score = lens opacities classification system III grading score; EPT = effective phacemulsification time; IOP = intraocular pressure; CDVA=corrected distance visual acuity; UDVA=uncorrected distance visual acuity; BDVA=best distance visual acuity; NOS = not otherwise specified; NR = not reported; NA = not applicable; NS = not statistically significant; FU = follow-up; FSL=femtosecond laser; FLACS=femtosecond laser-assisted cataract surgery.
Table 2: Characteristics of upcoming studies presented at recent conference proceedings or registered on ClinicalTrials.gov

<table>
<thead>
<tr>
<th>Author, Year</th>
<th>Abstract Title</th>
<th>Conference, Location, Year</th>
<th>Population; Study Design; Setting</th>
<th>Study Objectives</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chee (ongoing study, registered in 2012)</td>
<td>Prospective Evaluation of Circularity and Diameter of Femtosecond Laser Versus Manual Anterior Capsulotomy in Singapore National Eye Centre (1118)</td>
<td>ClinicalTrials.gov Online only</td>
<td>N=22 Prospective, randomized study Singapore National Eye Centre, Singapore</td>
<td>Evaluate the circularity of the anterior capsulotomy performed by FLACS versus conventional cataract surgery.</td>
</tr>
<tr>
<td>Gayton, 2013</td>
<td>Clinical Experience With Femtosecond Laser–Assisted Cataract Surgery</td>
<td>ASCRS Paper. San Francisco, CA. 2013</td>
<td>N=5 patients NR NR</td>
<td>Femtosecond laser technology use in cataract surgery has several differences that can cause complications: 1) the anterior capsule is open prior to opening the eye therefore an anterior chamber collapse can result in anterior capsule tears, 2) large gas bubbles posterior to the lens can contribute to capsular block syndrome, 3) an incomplete capsulorrhexis can result in radial extension and 4) laser energy in the nucleus can be directed too anterior, too peripheral and too posterior. Adjustments to the surgical technique can help manage these complications appropriately.</td>
</tr>
<tr>
<td>Innovative Medical</td>
<td>Clear Corneal Incisions and Arcuate Incisions Utilizing FemtoSecond Laser Technology for Cataract Surgery</td>
<td>ClinicalTrials.gov Online only</td>
<td>N=29 patients Non-Randomized trial Loden Vision Centers, Tennessee, USA</td>
<td>The purpose of this study is to prove the efficacy and safety of the Femtosecond laser to create a clear corneal incision during cataract surgery.</td>
</tr>
<tr>
<td>Kurtz, 2009</td>
<td>A Prospective Single Center Clinical Study for Capsulotomy Using the LenSx 550 Laser</td>
<td>ClinicalTrials.gov Online only</td>
<td>N=60 Prospective Single Center Trial Semmelweis University, Hungary</td>
<td>The objective of this study is to evaluate the ability of the LenSx 550 laser to successfully perform anterior capsulotomy during cataract surgery.</td>
</tr>
<tr>
<td>Author, Year</td>
<td>Abstract Title</td>
<td>Conference, Location, Year</td>
<td>Population; Study Design; Setting</td>
<td>Study Objectives</td>
</tr>
<tr>
<td>-------------</td>
<td>--------------------------------------------------------------------------------</td>
<td>---------------------------------------------</td>
<td>------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Loden, 2011</td>
<td>Laser Cataract Surgery With the Femtosecond Laser Technology</td>
<td>ClinicalTrials.gov Online only</td>
<td>N=10 Non-Randomized trial Loden Vision Centers, Tennessee, USA</td>
<td>The purpose of this study is to prove the efficacy and safety of the Femtosecond laser to create a clear corneal incision during cataract surgery.</td>
</tr>
<tr>
<td>Mann, 2013</td>
<td>Reduction of Cumulative Disbursement of Energy With Femtosecond Laser Cataract</td>
<td>ASCRS Paper. San Francisco, CA. 2013</td>
<td>N=151 eyes NR NR</td>
<td>Pretreatment with the Catalys femtosecond laser for cataract surgery allows for a greater than fifty percent reduction in ultrasound power during cataract extraction with the Infiniti phacoemulsification system with Özil. This reduction in power may lead to quieter eyes with less edema and inflammation and a quicker visual recovery in the early postoperative period for femtosecond pretreatment group compared to a phacoemulsification group.</td>
</tr>
<tr>
<td>Naranjo, 2011</td>
<td>Laser Treatment of the Crystalline Lens</td>
<td>ClinicalTrials.gov Online only</td>
<td>N=75 A Prospective Single-Center Trial Mexico</td>
<td>The objective of this study is to evaluate the feasibility of the LensAR laser system to surgically intervene within the crystalline lens. The primary goal of this initial study is to establish safety parameters as compared with conventional phacoemulsification procedures and to evaluate the ability to provide an accurate and consistent anterior capsular opening (capsulotomy).</td>
</tr>
<tr>
<td>Ophthalmic Consultants of Long Island, 2012</td>
<td>Corneal Sensation and Incidence of Dry Eye Post Refractive Cataract Extraction With FemtoSecond Laser</td>
<td>ClinicalTrials.gov Online only</td>
<td>N=40 Prospective cohort study Ophthalmic Consultants of Long Island – Rockville Centre. USA</td>
<td>The study objective is to assess changes in corneal sensation and dry eye signs and symptoms following cataract extraction/femtosecond arcuate relaxing incisions. Our clinical hypothesis is to determine if a combination of cataract surgery and femtosecond arcuate relaxing incisions lead to a reduction in corneal sensation and the onset or worsening of dry eye signs and symptoms.</td>
</tr>
<tr>
<td>Prickett, 2013</td>
<td>Initial Resident Experience Performing Cataract Surgery with and without Femtosecond Laser (Conference proceeding)</td>
<td>ARVO Poster Session, 2013</td>
<td>N=44 eyes Observational study University of Illinois, USA</td>
<td>To document and compare the resident experience performing cataract surgery with femtosecond laser with standard cataract surgery performed without femtosecond laser.</td>
</tr>
<tr>
<td>Sándor, 2013</td>
<td>Comparison of early corneal peripheral endothelial cell loss following femtosecond laser – assisted cataract surgery and conventional phacoemulsification (Conference proceeding)</td>
<td>ARVO Poster Session, 2013</td>
<td>N=15 patients (N=15 eyes) Observational study Semmelweis University, Hungary</td>
<td>To compare early corneal peripheral endothelial cell loss after femtosecond laser – assisted cataract surgery and conventional phacoemulsification, using non-contact specular microscopy.</td>
</tr>
<tr>
<td>Author, Year</td>
<td>Abstract Title</td>
<td>Conference, Location, Year</td>
<td>Population; Study Design; Setting</td>
<td>Study Objectives</td>
</tr>
<tr>
<td>-------------</td>
<td>--------------------------------------------------------------------------------</td>
<td>-----------------------------</td>
<td>-----------------------------------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Shah, 2013</td>
<td>Assessment of Ease of Adoption of Femtosecond Cataract Surgery</td>
<td>ASCRS Poster San Francisco, CA 2013</td>
<td>NR NR NR</td>
<td>Examine the ease of use, compatibility of the system and quality of outcomes with femtosecond laser-assisted cataract surgery.</td>
</tr>
<tr>
<td>Vote, 2013</td>
<td>Postoperative Corneal Oedema and Endothelial Cell Loss After Femtosecond Laser Pretreatment Compared With Conventional Cataract Surgery</td>
<td>ASCRS Paper. San Francisco, CA. 2013</td>
<td>Patient n=140 Prospective case-control study NR</td>
<td>Femtosecond laser pretreatment followed by phacoemulsification cataract surgery is associated with a significant reduction in post-operative oedema and endothelial cell loss compared to conventional phacoemulsification.</td>
</tr>
</tbody>
</table>

Abbreviations: ASCRS = American Society of Cataract and Refractive Surgery; ASCRS♦ASO= A Symposium and Congress; ARVO= Association for Research in Vision and Ophthalmology; SPIE = the International Society for Optical Engineering; NR= not reported
DISCUSSION

We conducted a systematic review of the current FLACS literature, comparing the benefits of FLACS to conventional cataract surgery, the adverse events associated with FLACS and the influence of increasing surgical experience on these adverse events. We found moderate evidence of comparable CDVA outcomes between FLACS and conventional cataract surgery groups. We noted limited evidence for a reduction of EPT in the FSL compared to the conventional cataract surgery group. Furthermore, meta-analyses found no statistically significant differences between FSL and conventional groups in either CDVA or EPT. No studies reported findings related to quality of life outcomes or cost effectiveness of FLACS relative to conventional cataract surgery.

Several studies reporting adverse effects unique to FLACS noted docking failures to be common. These failures were successfully managed by a subsequent docking attempt. Rarely did these failures require aborting the FSL procedure, with successful completion by converting to conventional cataract surgery, resulting in no adverse outcomes. There were moderate adverse findings of orbital or ocular anatomical laser interface difficulties, causing either aborted FSL procedures or exclusion of these patients from the studies. The Catalys FSL platform, using the liquid-filled interface, was utilized in two studies of serial IOP measurements during and after the procedure. Transient elevation of IOP into the mid-20 to mid-30 mm Hg range during the FSL procedure was noted in these studies. No studies were found for IOP measurements using the Alcon LenSx FSL, which utilizes suction to effect docking. This interface mechanism has been noted to cause marked IOP elevations in other corneal refractive surgical applications.

Most of the included studies reported on the comparative risks of adverse effects between FSL and conventional cataract surgery. Reports of adverse events were similar between FSL and conventional groups, including IOL positioning, corneal thickness, macular edema and residual refractive error. The rate of postoperative corneal endothelial cell was noted to be significantly decreased in the FSL group in only one included medium-sized study (N=201).16

The association between the experience of the surgeon and FLACS adverse effects was limited to three eligible studies, two of which were related. These studies reported mixed results of surgical experience reducing the incidence of FLACS adverse events, with very low strength of evidence.

We conducted an update search on September 18, 2013 and found two observational studies that reported decreased EPT with FSL,46,47 consistent with the trend seen among other studies included in our review. We also identified two recent studies that found decreased initial postoperative inflammation with FSL,47,48 although after three months no differences were observed between FSL and conventional cataract surgery.48

Although there were significant limitations with the body of literature, we found FLACS to be comparable to conventional cataract surgery. We found no evidence that FLACS differs from conventional cataract surgery on measures of safety and effectiveness. The unique risks associated with FLACS are primarily related to laser docking interface difficulties, which may be reduced with increasing surgical experience with the procedure. The comparative adverse event risks of FLACS and conventional surgery were similar. Complications rates in FLACS cohorts were found to be reduced or unchanged by surgical experience in the included studies of this review.
There were methodological concerns for the included studies that represent potential sources of bias that threaten the validity of study findings. Many studies had small sample sizes, with the potential for difficulty in analyzing data for low-risk events, and follow-up times and outcomes reported were often variable, making study comparisons problematic. In addition, study methods were often unclear, particularly with regard to the application of inclusion and exclusion criteria for FSL treatment groups and the enrollment of treatment and control cohorts. Often studies excluded patients with denser cataracts, comorbidities and those deemed uncooperative. In addition, many study protocols called for patients self-selecting into FSL or conventional surgery groups. Further, most studies evaluated similarities between treatment and control groups only for gender and age.

All of the FSL platforms require the orbital anatomy to be accessible and the cornea to be suitable for successful laser docking. Two of the eligible studies in this review specifically excluded patients in the FSL group, who had “deep-set eyes” or “narrow palpebral fissures”. Similarly, an adequate laser/corneal interface requires a pristine corneal surface. Most of the studies excluded patients from the laser treatment groups with corneal pathology such as scarring, previous corneal surgery and high degrees of corneal astigmatism, limiting generalizability of findings to those patients for whom FLACS is appropriate.

Similar exclusion criteria issues were noted in studies for dense cataracts as the FSL is unable to perform photo disruption in tissues that are not optically clear. The Schiempflug nuclear density grading (LOC III score of increasing density from 1-5) was reported at baseline in a minority of the comparative studies. Here, in the FSL groups, the LOCS III scores ranged from 2.13 to 2.59; only patients with mild to moderate density cataracts were enrolled, specifically excluding patients with dense cataracts.

The FSL procedure is unsuitable for patients who are unable to cooperate, for any reason. Thus, some studies excluded patients from the FSL groups who were “uncooperative”, or with hemifacial spasm. Transient elevations of IOP limit FLACS suitability for patients with high-risk glaucoma, another exclusion criteria found in many studies. Patients with other medical co-morbidities, such as kyphosis and movement or behavioral disorders, were found to be unacceptable for FLACS procedures. The careful patient selection in studies of FLACS to date may significantly limit the generalizability of findings to VA cataract surgical populations.

Operating room logistics and efficiencies are made more cumbersome by the need for a two-suite surgery staging for each patient. Each patient undergoes the FLACS procedure beneath the FLS platform and is moved into a second, sterile location in the operating room for the completion of the surgery. In addition, multiple laser docking attempts can extend the operating room time for each patient. This added complexity and duration of the surgical procedure may adversely impact surgical backlogs.

Device manufacturers are closely associated with most of the study authors and the majority of included studies (all but two) report financial conflicts of interest. Eligible studies were also clustered around a limited number of geographic sites and conducted by the same team of coauthors. All four of the included randomized trials were conducted by the same research group, and every surgery (FSL or conventional) was completed by the same surgeon study co-author. It is also unclear whether or not there was any overlap in the study patient populations of these
trials, given they were conducted at the same site and in what seems to be a similar timeframe.

Most of the studies in this review involved highly experienced, high-volume surgeons, supported by similarly experienced surgical teams. These findings may not apply to VA surgeons, especially with regard to ophthalmology residency training programs. The few studies which reported decreasing complication rates with increased surgical experience must be considered when evaluating the suitability of introducing FLACS into a training program environment.

The eligible studies in this review did not include any cost-effectiveness or quality of life data. The non-laser portion of the disposable costs for FLACS and conventional phacoemulsification surgery are comparable, as both involve irrigation, aspiration and phacoemulsification. The additional, incremental cost of FLACS is the $150-300 per patient charge for the sterile, single-use patient interface device. The approximate initial cost of the FSL equipment is $500,000. Future studies assessing the cost-effectiveness and incremental changes to quality of life associated with FLACS and conventional cataract surgery will be needed to provide additional information to guide procedure adoption decisions.

**FUTURE STUDIES**

Modern, conventional cataract surgery is associated with very low risks of sight-threatening complications. In this review, FLACS appears to be comparable to conventional cataract surgery, though the evidence base is limited. Greater numbers of randomized control trials (RCTs) with larger sample cohort sizes are desirable to allow detection of the relative risks of rare events. Assessment blinding is problematic, as FLACS patients are aware of their participation in the FSL treatment arm, as are the assessors due to the unique appearance of the laser versus the manual incisions. Studies that are sufficiently powered and well designed should be insulated from the device manufacturers to eliminate this potential bias. Head to head trials between FSL platforms should assist in informing potential users of their relative risks and benefits. Studies from groups other than those few included in this review should provide a more global perspective of FLACS. The applicability of the FSL technology to the overall cataract population has not been explored by the eligible studies in this review. Further studies regarding the suitability of FSL for patients with the co-morbidities found in the VA population (i.e. dense cataracts, glaucoma, corneal pathology) and studies assessing the costs relative to benefits expected from FLACS and conventional surgery will be key to determining the feasibility of widespread adoption of this procedure.
CONCLUSIONS

This systematic review found visual outcomes (CDVA) and EPT to be similar in FLACS and conventional surgery, while quality of life and cost-effectiveness outcomes were not reported. The evidence for the relative benefit of FLACS was limited by reliance on small to moderately-sized prospective cohort studies, nearly all of which had stated financial conflicts of interest. Adverse events unique to FLACS involved difficulties in laser docking or patient suitability for the procedure. Many patients were excluded from the FSL treatment groups for orbital, corneal, cataract density, or medical co-morbidities. Comparative adverse events in FLACS and conventional surgery were found to be similar for IOL positioning, corneal thickness, macular edema and residual refractive error. A few studies reported mixed results of the effect of surgical experience on the incidence of FLACS adverse events.

Table 3: Summary of the evidence on the effects of femtosecond laser assisted cataract surgery

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Findings</th>
<th>Strength of Evidence</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Visual acuity</td>
<td>2 RCTs (N=189) 4 NRCS (N=306)</td>
<td>No significant differences</td>
<td>Low</td>
</tr>
<tr>
<td>Effective phacoemulsification time</td>
<td>1 RCT (N=76) 4 NRCS (N=615) 1 NCS (N=160)</td>
<td>Mixed findings</td>
<td>Low</td>
</tr>
<tr>
<td>Quality of life</td>
<td>None</td>
<td>None</td>
<td>No evidence</td>
</tr>
<tr>
<td>Intraoperative complications*</td>
<td>3 NRCS (N=1,900) 3 NCS (N=285)</td>
<td>Higher IOP for FLACS; Few additional complications for FLACS</td>
<td>Moderate to Low</td>
</tr>
<tr>
<td>Postoperative complications**</td>
<td>1 RCT (N=76) 1 NRCS (N=150) 1 NCS (N=160)</td>
<td>Mixed findings</td>
<td>Low</td>
</tr>
<tr>
<td>Costs</td>
<td>None</td>
<td>None</td>
<td>No evidence</td>
</tr>
</tbody>
</table>

Abbreviations: RCT = randomized controlled trial; NRCS = non-randomized comparative studies; NCS = non-comparative studies; FLACS = femtosecond laser assisted cataract surgery; EPT = effective phacoemulsification time; IOP = intraocular pressure.
* Intraoperative complications include: capsular blockage, capsular tear, dislocated nucleus, docking failure
** Postoperative complications include: infection, retinal swelling/cystoid macular edema, intraocular decentration, corneal edema
REFERENCES


